XML 107 R47.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) € in Thousands, $ in Thousands | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2023 USD ($) | Jul. 31, 2020 EUR (€)
Notes to the Consolidated Statements of Operations |  |  |  |  |
Upfront and milestones payments included in contract liabilities | € 92,680 | € 107,308 |  |  |
Revenue recognized from upfront and milestones payments | 31,051 | 44,787 | € 67,828 |  |
GSK |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |
Upfront Payments Received Or Receivable | 220,000 |  |  |  | € 120,000
Upfront and milestones payments included in contract liabilities | 88,715 | 102,804 |  |  |
Revenue recognized from upfront and milestones payments | 29,089 | 42,690 | 51,728 |  |
Boehringer Ingelheim |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |
Upfront Payments Received Or Receivable | 30,000 |  |  |  |
Revenue recognized from upfront and milestones payments |  |  | 14,003 |  |
Genmab |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |
Upfront Payments Received Or Receivable | 8,937 |  |  | $ 10,000 |
Upfront and milestones payments included in contract liabilities | 2,383 | 3,575 |  |  |
Revenue recognized from upfront and milestones payments | 1,192 | 1,787 | 1,787 |  |
CRISPR |  |  |  |  |
Notes to the Consolidated Statements of Operations |  |  |  |  |
Upfront Payments Received Or Receivable | 3,947 |  |  | $ 4,500 |
Upfront and milestones payments included in contract liabilities | 1,582 | 929 |  |  |
Revenue recognized from upfront and milestones payments | € 770 | € 310 | € 310 |  |

X
- Definition Represents of disclosure of notes to the consolidated financial statements. + References No definition available. + Details
Name: | cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems
Namespace Prefix: | cvac_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of upfront payments of the company included in contract liabilities. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsIncludedInContractLiabilities
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of upfront payments received or receivable by the company. + References No definition available. + Details
Name: | cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix: | cvac_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 116 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_BoehringerIngelheimMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_GenmabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MajorCustomersAxis=cvac_CrisprMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |